GlaxoSmithKline
-
GlaxoSmithKline and XenoPort receive FDA approval for Horizant
GlaxoSmithKline and XenoPort, Inc announced that the US Food and Drug Administration (FDA) has approved Horizant (gabapentin enacarbil) extended-release tablets for the treatment of moderate-to-severe primary Restless Legs Syndrome in adults. Horizan…
GlaxoSmithKline | 08 April 2011
-
Vectura and GlaxoSmithKline sign licensing agreement
GlaxoSmithKline ( GSK ) have signed a worldwide non-exclusive agreement to license some of Vectura 's dry powder drug formulation patents in relation to two late stage development compounds in GSK's respiratory product pipeline. Under the terms of…
GlaxoSmithKline | 02 September 2010
-
GSK Announces Systemic Lupus Erythematosus Trial Results
GlaxoSmithKline (GSK) and Human Genome Sciences have announced secondary endpoints from BLISS-76, the second of two pivotal Phase 3 trials of Benlysta (belimumab) in seropositive patients with systemic lupus erythematosus (SLE). At Week 76 in the…
GlaxoSmithKline | 29 April 2010
-
GlaxoSmithKline and Genmab Announce Results for Rheumatoid Arthritis Study
GlaxoSmithKline (GSK) and Genmab have announced preliminary results from a Phase III study of ofatumumab administered intravenously for the treatment of Rheumatoid Arthritis (RA) in patients who have an inadequate response to methotrexate. The st…
GlaxoSmithKline | 13 August 2009
-
GlaxoSmithKline: Government Orders for Pandemic (H1N1) 2009 Vaccine
GlaxoSmithKline (GSK) has confirmed that it has contracts in place to supply 195 million doses of its pandemic (H1N1) 2009 adjuvanted influenza vaccine. It has a variety of agreements in place with the US government to supply pandemic products worth …
GlaxoSmithKline | 10 August 2009
-
GSK and Shenzhen Neptunus to Develop Vaccines in China
GlaxoSmithKline (GSK) has entered into an agreement to form a Joint Venture (JV) with Shenzhen Neptunus Interlong Bio-Technique (Shenzhen Neptunus), focused on developing and manufacturing influenza vaccines for the Chinese market. The alliance wi…
GlaxoSmithKline | 19 June 2009
-
Relenza: Sales in Q1
Biota Holdings has received notification from GlaxoSmithKline (GSK) that Relenza sales were US$327.5 million and indicative royalties were US$22.9 million, for the three months ended 31 March 2009. Indicative royalties for the nine months to 31 Ma…
GlaxoSmithKline | 04 May 2009
-
GSK Increases Imports of Relenza into Japan
GlaxoSmithKline KK (GSK) has decided to increase the imports of its anti-influenza virus drug, Relenza (generic name: zanamivir hydrate) into Japan. Due to reports that the prevailing A/H1N1 influenza virus has become resistant to another anti-…
GlaxoSmithKline | 24 February 2009
-
Cytokinetics Retains Rights to Ispinesib and SB-743921
GlaxoSmithKline (GSK) has informed Cytokinetics that it will not exercise its option to license ispinesib or SB-743921 as provided under the Collaboration and License Agreement entered into by the companies in 2001. All rights to ispinesib and SB…
GlaxoSmithKline | 23 January 2009
-
Amira Pharmaceuticals And GlaxoSmithKline Enter Global Agreement For FLAP Inhibitor Program
Amira Pharmaceuticals and GlaxoSmithKline announced they have entered into a worldwide exclusive agreement to develop, manufacture and commercialize FLAP (5-Lipoxygenase Activating Protein) inhibitors for the treatment of respiratory and cardiovascul…
GlaxoSmithKline | 08 February 2008
